CrossrefInfokarte
Cost-Effectiveness Analysis of Lebrikizumab versus Dupilumab for Patients with Severe Atopic Dermatitis in Austria
ClinicoEconomics and Outcomes Research · 2026-11 · Volume 18 · 1-10
DOI: 10.2147/ceor.s637548 ↗Abstract
Kein Abstract verfügbar.
EUVIMED